Sanofi Schedule 13G passive stakes

Amundi and Amundi Asset Management have updated their Schedule 13G filing regarding their beneficial ownership of Sanofi common stock.

Sanofi has reported beneficial ownership of 5.71% of AgomAb Therapeutics' common shares, totaling 2,783,096 shares.

Amundi and Amundi Asset Management have filed a Schedule 13G, reporting beneficial ownership of 5.04% of Sanofi's common stock and American Depositary Receipts.

Amundi and Amundi Asset Management have filed an amendment to their Schedule 13G, reporting beneficial ownership of 5.21% of Sanofi's common stock and American Depositary Receipts.

Amundi and Amundi Asset Management report a 5.03% beneficial ownership stake in Sanofi, primarily for investment purposes.

Amundi and its subsidiary, Amundi Asset Management US, Inc., have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 4.8% in Sanofi's common stock and American Depositary Receipts as of March 31, 2025.

Sanofi has filed an amended Schedule 13G, revealing its beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares as of April 23, 2025.

Sanofi has filed a Schedule 13G, revealing a beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.8% passive beneficial ownership stake in Sanofi's common stock as of March 31, 2025.

Amundi and its subsidiary Amundi Asset Management US, Inc. have filed an updated Schedule 13G, disclosing a 5.1% beneficial ownership stake in Sanofi as of December 31, 2024.